ADMA
Price
$20.57
Change
+$0.63 (+3.16%)
Updated
Jun 6, 04:09 PM (EDT)
Capitalization
4.76B
61 days until earnings call
QNTM
Price
$15.46
Change
+$1.71 (+12.44%)
Updated
Jun 6, 04:59 PM (EDT)
Capitalization
39.43M
Interact to see
Advertisement

ADMA vs QNTM

Header iconADMA vs QNTM Comparison
Open Charts ADMA vs QNTMBanner chart's image
ADMA Biologics
Price$20.57
Change+$0.63 (+3.16%)
Volume$1.13K
Capitalization4.76B
Quantum Biopharma
Price$15.46
Change+$1.71 (+12.44%)
Volume$4.24K
Capitalization39.43M
ADMA vs QNTM Comparison Chart
Loading...
ADMA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
QNTM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ADMA vs. QNTM commentary
Jun 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADMA is a Hold and QNTM is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 06, 2025
Stock price -- (ADMA: $19.94 vs. QNTM: $13.73)
Brand notoriety: ADMA and QNTM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ADMA: 48% vs. QNTM: 91%
Market capitalization -- ADMA: $4.76B vs. QNTM: $39.43M
ADMA [@Biotechnology] is valued at $4.76B. QNTM’s [@Biotechnology] market capitalization is $39.43M. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ADMA’s FA Score shows that 2 FA rating(s) are green whileQNTM’s FA Score has 0 green FA rating(s).

  • ADMA’s FA Score: 2 green, 3 red.
  • QNTM’s FA Score: 0 green, 5 red.
According to our system of comparison, ADMA is a better buy in the long-term than QNTM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ADMA’s TA Score shows that 3 TA indicator(s) are bullish while QNTM’s TA Score has 3 bullish TA indicator(s).

  • ADMA’s TA Score: 3 bullish, 6 bearish.
  • QNTM’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, QNTM is a better buy in the short-term than ADMA.

Price Growth

ADMA (@Biotechnology) experienced а +0.86% price change this week, while QNTM (@Biotechnology) price change was +9.14% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +11.55%. For the same industry, the average monthly price growth was +17.24%, and the average quarterly price growth was +3.49%.

Reported Earning Dates

ADMA is expected to report earnings on Aug 06, 2025.

QNTM is expected to report earnings on Mar 28, 2025.

Industries' Descriptions

@Biotechnology (+11.55% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ADMA($4.76B) has a higher market cap than QNTM($39.4M). QNTM YTD gains are higher at: 273.098 vs. ADMA (16.268). ADMA has higher annual earnings (EBITDA): 98.8M vs. QNTM (-10.58M). ADMA has more cash in the bank: 86.7M vs. QNTM (6.61M). QNTM has less debt than ADMA: QNTM (373K) vs ADMA (111M). ADMA has higher revenues than QNTM: ADMA (383M) vs QNTM (0).
ADMAQNTMADMA / QNTM
Capitalization4.76B39.4M12,081%
EBITDA98.8M-10.58M-934%
Gain YTD16.268273.0986%
P/E Ratio23.74N/A-
Revenue383M0-
Total Cash86.7M6.61M1,312%
Total Debt111M373K29,759%
FUNDAMENTALS RATINGS
ADMA vs QNTM: Fundamental Ratings
ADMA
QNTM
OUTLOOK RATING
1..100
824
VALUATION
overvalued / fair valued / undervalued
1..100
77
Overvalued
66
Overvalued
PROFIT vs RISK RATING
1..100
13100
SMR RATING
1..100
2895
PRICE GROWTH RATING
1..100
4434
P/E GROWTH RATING
1..100
99100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

QNTM's Valuation (66) in the null industry is in the same range as ADMA (77) in the Biotechnology industry. This means that QNTM’s stock grew similarly to ADMA’s over the last 12 months.

ADMA's Profit vs Risk Rating (13) in the Biotechnology industry is significantly better than the same rating for QNTM (100) in the null industry. This means that ADMA’s stock grew significantly faster than QNTM’s over the last 12 months.

ADMA's SMR Rating (28) in the Biotechnology industry is significantly better than the same rating for QNTM (95) in the null industry. This means that ADMA’s stock grew significantly faster than QNTM’s over the last 12 months.

QNTM's Price Growth Rating (34) in the null industry is in the same range as ADMA (44) in the Biotechnology industry. This means that QNTM’s stock grew similarly to ADMA’s over the last 12 months.

ADMA's P/E Growth Rating (99) in the Biotechnology industry is in the same range as QNTM (100) in the null industry. This means that ADMA’s stock grew similarly to QNTM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ADMAQNTM
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
75%
Bearish Trend 2 days ago
89%
Momentum
ODDS (%)
Bearish Trend 2 days ago
83%
N/A
MACD
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 3 days ago
75%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
76%
Bullish Trend 2 days ago
74%
Advances
ODDS (%)
Bullish Trend 4 days ago
87%
Bullish Trend 4 days ago
83%
Declines
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
ADMA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
QNTM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
EURL33.620.12
+0.36%
Direxion Daily FTSE Europe Bull 3X ETF
EPP49.360.06
+0.12%
iShares MSCI Pacific ex Japan ETF
SOLR26.35N/A
N/A
SmartETFs Sustainable Energy II ETF
CLOX25.48-0.03
-0.12%
Eldridge AAA CLO ETF
CVLC73.42-0.39
-0.53%
Calvert US Large-Cp Cor Rspnb ETF

ADMA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ADMA has been loosely correlated with IOVA. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ADMA jumps, then IOVA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADMA
1D Price
Change %
ADMA100%
-1.92%
IOVA - ADMA
46%
Loosely correlated
-1.91%
TARS - ADMA
43%
Loosely correlated
+3.35%
IMTX - ADMA
42%
Loosely correlated
+1.04%
ACLX - ADMA
41%
Loosely correlated
+1.18%
RVMD - ADMA
40%
Loosely correlated
-0.42%
More